New insider activity at AbbVie ( (ABBV) ) has taken place on August 14, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Azita Saleki-Gerhardt, the Executive Vice President and Chief Operations Officer at AbbVie, has recently sold 42,370 shares of AbbVie stock. This transaction is valued at an impressive $8,407,055.
Recent Updates on ABBV stock
Recent developments in AbbVie’s stock are primarily driven by updates on several ongoing clinical studies. AbbVie is conducting multiple studies, including a Phase 1/2 study on the BCL-2 inhibitor ABBV-453 for multiple myeloma, a Phase 1b/2 study on Telisotuzumab Adizutecan and Budigalimab for non-squamous NSCLC, a Phase 3 study on Upadacitinib for pediatric Crohn’s Disease, and a Phase 3 study for Takayasu Arteritis. These studies are crucial as they explore new treatment options in competitive markets, potentially expanding AbbVie’s product portfolio. Positive results from these studies could enhance AbbVie’s market position and influence investor sentiment positively, as they address critical needs in their respective fields. The outcomes of these studies are significant for AbbVie’s stock performance, given the competitive landscape in these therapeutic areas.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Outperform.
AbbVie’s strong earnings call performance and robust growth in key segments are the primary drivers of its stock score. Financial leverage and high P/E ratio present risks, but the company’s raised guidance and strategic growth initiatives in neuroscience and immunology support a positive outlook.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
YTD Price Performance: 16.50%
Average Trading Volume: 5,812,566
Technical Sentiment Signal: Strong Buy
Current Market Cap: $350.9B